Haisco Pharmaceutical (SHE:002653) obtained regulatory approval from China's drug administrator for the expansion in the indication of anruikefen injection, according to a Tuesday filing with the Shenzhen bourse.
The drug is indicated to treat moderate-to-severe pruritus associated with chronic kidney disease in patients undergoing maintenance hemodialysis, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 2% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments